Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 1/20 | 0.41 |
| ▸ | MAPK14 | Q16539 | 7/20 | 0.40 |
| ▸ | CDK4 | P11802 | 1/20 | 0.38 |
| ▸ | CDK2 | P24941 | 1/20 | 0.38 |
| ▸ | GABRA1 | P14867 | 3/20 | 0.38 |
| ▸ | GABRB2 | P47870 | 3/20 | 0.38 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.38 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.38 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.38 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.38 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.38 |
| ▸ | ACVR2B | Q13705 | 1/20 | 0.38 |
| ▸ | MYLK | Q15746 | 1/20 | 0.38 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.38 |
| ▸ | PRKD2 | Q9BZL6 | 1/20 | 0.38 |
| ▸ | NLK | Q9UBE8 | 1/20 | 0.38 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.38 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.38 |
| ▸ | HTR5A | P47898 | 1/20 | 0.36 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1691704 | 0.83 | GABRA1 (0.54) | TGFBR1GABRA1GABRB2 | |
| SCHEMBL1691132 | 0.81 | PRNP (0.47) | MAPK14GABRA1GABRB2PRKD3PRKD2 | |
| SCHEMBL1691613 | 0.81 | SLC2A1 (0.45) | MAPK14GABRB2MAPK11SLC2A2 | |
| SCHEMBL1691693 | 0.81 | SLC2A1 (0.45) | TGFBR1CDK4CDK2GABRA1GABRB2 | |
| SCHEMBL1691779 | 0.80 | DPP4 (0.49) | SLC2A2 | |
| SCHEMBL18977271 | 0.78 | CDK2 (0.39) | CDK4CDK2GABRA1GABRB2SLC2A2 | |
| SCHEMBL1691379 | 0.74 | MAPK14 (0.35) | TGFBR1MAPK14PRKD3PRKD2 | |
| SCHEMBL1691484 | 0.74 | SLC2A1 (0.60) | GABRB2SLC2A2 | |
| SCHEMBL1691361 | 0.72 | DYRK1A (0.49) | MAPK14PRKD3MAPK9ROCK1ALK | |
| SCHEMBL1691390 | 0.71 | DPP4 (0.39) | MAPK14PRKD3MAPK11PRKD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160113893-A1 | NEW THERAPEUTIC USES OF ENZYME INHIBITORS | UPSHER-SMITH LABORATORIES, INC. | 2016-04-28 | — | — | US | claimed |
| US-20150239905-A1 | IMIDAZOPYRIDINE COMPOUNDS | BIOVITRUM AB (PUBL) (SE) | 2015-08-27 | — | — | US | claimed |
| EP-2376490-B1 | IMIDAZOPYRIDINE COMPOUNDS | PROXIMAGEN LTD (GB) | 2013-01-23 | — | — | EP | claimed |
| US-20120010188-A1 | Imidazopyridine Compounds | PROMIMAGEN LTD. (GB) | 2012-01-12 | — | — | US | claimed |
| EP-2376490-A1 | IMIDAZOPYRIDINE COMPOUNDS | Proximagen Limited (GB) | 2011-10-19 | — | — | EP | claimed |
| WO-2010064020-A1 | IMIDAZOPYRIDINE COMPOUNDS | PROXIMAGEN LTD. (GB) | 2010-06-10 | — | — | WO | claimed |
| EP-3777846-A1 | VAP-1 INHIBITORS FOR TREATING PAIN | BenevolentAI Cambridge Limited (GB) | 2021-02-17 | — | — | EP | disclosed |
| US-20200397764-A1 | VAP-1 INHIBITORS FOR TREATING PAIN | PROXIMAGEN, LLC | 2020-12-24 | — | — | US | disclosed |
| WO-2017098236-A1 | VAP-1 INHIBITORS FOR TREATING PAIN | PROXIMAGEN LIMITED (GB) | 2017-06-15 | — | — | WO | disclosed |
| US-20160113893-A1 | NEW THERAPEUTIC USES OF ENZYME INHIBITORS | UPSHER-SMITH LABORATORIES, INC. | 2016-04-28 | — | — | US | disclosed |
| US-20160113893-A1 | NEW THERAPEUTIC USES OF ENZYME INHIBITORS | UPSHER-SMITH LABORATORIES, INC. | 2016-04-28 | — | — | US | disclosed |
| US-20160101072-A1 | Therapeutic uses of enzyme inhibitors | PROXIMAGEN LIMITED (GB) | 2016-04-14 | — | — | US | disclosed |
| US-20160101072-A1 | Therapeutic uses of enzyme inhibitors | PROXIMAGEN LIMITED (GB) | 2016-04-14 | — | — | US | disclosed |
| EP-2376490-B1 | IMIDAZOPYRIDINE COMPOUNDS | PROXIMAGEN LTD (GB) | 2013-01-23 | — | — | EP | disclosed |
| US-20120010188-A1 | Imidazopyridine Compounds | PROMIMAGEN LTD. (GB) | 2012-01-12 | — | — | US | disclosed |
| US-20120010188-A1 | Imidazopyridine Compounds | PROMIMAGEN LTD. (GB) | 2012-01-12 | — | — | US | disclosed |
| US-20120010188-A1 | Imidazopyridine Compounds | PROMIMAGEN LTD. (GB) | 2012-01-12 | — | — | US | disclosed |
| EP-2376490-A1 | IMIDAZOPYRIDINE COMPOUNDS | Proximagen Limited (GB) | 2011-10-19 | — | — | EP | disclosed |
| WO-2010064020-A1 | IMIDAZOPYRIDINE COMPOUNDS | PROXIMAGEN LTD. (GB) | 2010-06-10 | — | — | WO | disclosed |
| WO-2010064020-A1 | IMIDAZOPYRIDINE COMPOUNDS | PROXIMAGEN LTD. (GB) | 2010-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200397764-A1 | VAP-1 INHIBITORS FOR TREATING PAIN | VAPB, VAPA, OPRL1 | TGFBR1 2597/4885MAPK14 3676/4885CDK4 4551/4885 |
| US-20120010188-A1 | Imidazopyridine Compounds | SSB, MIF, IDO1 | TGFBR1 2881/4885MAPK14 3550/4885CDK4 2433/4885 |
| US-20160113893-A1 | NEW THERAPEUTIC USES OF ENZYME INHIBITORS | VAPB, VAPA, AOX1 | TGFBR1 3279/4885MAPK14 4582/4885CDK4 4435/4885 |
| US-20150239905-A1 | IMIDAZOPYRIDINE COMPOUNDS | SSB, MIF, IDO1 | TGFBR1 2881/4885MAPK14 3550/4885CDK4 2433/4885 |
| US-20160101072-A1 | Therapeutic uses of enzyme inhibitors | VAPB, VAPA, AOX1 | TGFBR1 3066/4885MAPK14 4744/4885CDK4 4172/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.